What Are the Risks of Taking Modafinil?

Modafinil is a prescription wakefulness-promoting drug used to improve excessive sleepiness associated with narcolepsy, obstructive sleep apnea and shift work disorder. Compared with older stimulants, it has generally been regarded as relatively well tolerated, but that does not mean it is free of meaningful risks.

The current PROVIGIL prescribing information lists common adverse effects such as headache, nausea, nervousness, anxiety and insomnia, as well as less common but potentially serious skin, allergic, psychiatric and cardiovascular reactions. Modafinil also has recognised abuse potential and can interact with several medications.

What Are the Most Common Side Effects of Modafinil?

In pooled placebo-controlled trials involving patients with narcolepsy, obstructive sleep apnea or shift work disorder, headache occurred in 34% of PROVIGIL-treated patients compared with 23% receiving placebo. Nausea occurred in 11% versus 3%, nervousness in 7% versus 3%, anxiety in 5% versus 1%, insomnia in 5% versus 1%, and dizziness in 5% versus 4%.

Other adverse reactions reported more often with PROVIGIL included diarrhea, dyspepsia, dry mouth, reduced appetite, chest pain, hypertension, palpitations and tachycardia. In placebo-controlled trials comparing 200, 300 and 400 mg/day, headache and anxiety were dose-related.

Among 934 people who received PROVIGIL in placebo-controlled trials, 8% discontinued because of an adverse reaction compared with 3% of those receiving placebo. Headache was the most frequent reason for discontinuation, followed by reactions including nausea, anxiety, dizziness, insomnia, chest pain and nervousness.

Can Modafinil Cause Serious Skin or Allergic Reactions?

The PROVIGIL prescribing information reports rare cases of Stevens-Johnson syndrome, toxic epidermal necrolysis and drug rash with eosinophilia and systemic symptoms, or DRESS, in adults and children during postmarketing use, as well as serious rash requiring hospitalisation and discontinuation of treatment.

Nearly all reported serious rashes associated with modafinil developed within 1 to 5 weeks after treatment began, although isolated cases have appeared after longer periods of use. The prescribing information states that there are no known factors that reliably predict who will develop a serious reaction or how severe it will become.

Modafinil has also been associated with angioedema and other hypersensitivity reactions. Multi-organ hypersensitivity reactions have occurred shortly after treatment began and have involved symptoms such as fever, rash, myocarditis, hepatitis, abnormal liver tests and changes in blood cell counts. At least one fatality has been reported in postmarketing experience.

Because a benign rash cannot reliably be distinguished from a potentially serious one when it first appears, the prescribing information recommends discontinuing PROVIGIL at the first sign of rash unless the rash is clearly unrelated to the drug.

Can Modafinil Cause Psychiatric Side Effects?

In controlled trials, psychiatric symptoms that led some patients to discontinue modafinil included anxiety, nervousness, insomnia, confusion, agitation and depression, while postmarketing reports have included mania, delusions, hallucinations, suicidal ideation and aggression, with some cases requiring hospitalisation.

The prescribing information describes one healthy volunteer who developed paranoid delusions, auditory hallucinations and ideas of reference while taking multiple daily 600 mg doses of modafinil during sleep deprivation. The symptoms resolved after the drug was discontinued.

PROVIGIL therefore carries a specific warning for people with a history of psychosis, depression or mania. The label advises considering discontinuation if psychiatric symptoms develop during treatment.

Does Modafinil Affect Heart Rate or Blood Pressure?

Short-term controlled trials lasting up to three months did not show clinically significant differences in average systolic or diastolic blood pressure between PROVIGIL and placebo. However, 2.4% of patients taking PROVIGIL required new or increased antihypertensive medication compared with 0.7% receiving placebo. Among patients with obstructive sleep apnea, the figures were 3.4% and 1.1%, respectively.

Cardiovascular adverse reactions reported in clinical studies have included chest pain, palpitations, shortness of breath and transient ischemic changes on electrocardiograms in particular patients. The prescribing information recommends increased monitoring of heart rate and blood pressure when appropriate and advises caution in people with known cardiovascular disease.

Kim’s 2012 review also describes evidence that modafinil increases resting heart rate and blood pressure and raises plasma and urinary norepinephrine as well as urinary epinephrine. The author interpreted these findings as evidence of peripheral sympathomedullary activation.

Can Modafinil Be Abused or Lead to Dependence?

PROVIGIL is classified as a Schedule IV controlled substance in the United States.

The prescribing information states that modafinil can produce psychoactive and euphoric effects along with changes in mood, perception, thinking and feelings that resemble those produced by other central nervous system stimulants. In an abuse-potential study involving people experienced with drugs of abuse, modafinil produced psychoactive and euphoric effects consistent with other scheduled stimulants.

Modafinil binds to the dopamine transporter and inhibits dopamine reuptake, increasing extracellular dopamine in some brain regions. Kim’s review discusses evidence that dopamine levels rise in the nucleus accumbens, a region involved in drug reward, and argues that this provides a biological basis for concern about abuse potential.

Physical dependence appears less clearly established: in one placebo-controlled trial, no withdrawal symptoms were reported during 14 days of observation after nine weeks of modafinil treatment, although sleepiness returned in patients with narcolepsy.

What Medications Can Interact With Modafinil?

By inducing CYP3A4/5, modafinil may lower blood concentrations of drugs metabolised through this pathway, including steroidal contraceptives, cyclosporine, midazolam and triazolam.

PROVIGIL may reduce the effectiveness of steroidal contraceptives during treatment and for one month after the drug is stopped. The label recommends using an alternative or additional contraceptive method during this period.

Modafinil also inhibits CYP2C19, which can increase exposure to medications including phenytoin, diazepam, propranolol, omeprazole and clomipramine. The prescribing information recommends more frequent monitoring of prothrombin time or INR when modafinil is used with warfarin and advises caution when it is combined with monoamine oxidase inhibitors.

Does Modafinil Replace the Need for Sleep?

The PROVIGIL Medication Guide states that the drug does not take the place of getting enough sleep. It also warns that patients with excessive sleepiness may not return to normal levels of wakefulness and may still need to avoid driving or other potentially dangerous activities.

Kim reviewed studies in which modafinil improved psychomotor vigilance after prolonged wakefulness. In one comparison after 44 hours without sleep, modafinil, dextroamphetamine and caffeine all improved vigilance relative to placebo. Modafinil produced fewer subjectively reported adverse effects than caffeine or dextroamphetamine in that experiment.

The same review points out that sleep deprivation itself produces physiological effects that a wake-promoting drug does not necessarily prevent. Experimental evidence cited by Kim links prolonged sleep deprivation with stress responses, impaired immune function and increased susceptibility to infection.

Some studies reviewed by Kim found little effect from modafinil on recovery sleep, while others suggested that recovery sleep could be impaired after sleep deprivation.

Who May Need Extra Caution With Modafinil?

People with cardiovascular disease may require increased monitoring, particularly of heart rate and blood pressure. Patients with a history of psychosis, depression or mania should also be monitored for new or worsening psychiatric symptoms. People with a history of drug or stimulant abuse should be observed for signs of misuse, such as increasing doses or drug-seeking behaviour.

Modafinil clearance is reduced in severe hepatic impairment, and the recommended dose is therefore reduced by half in these patients. Clearance may also be reduced in older adults, for whom lower doses and closer monitoring may be appropriate.

Reports associated with modafinil or armodafinil use during pregnancy have included intrauterine growth restriction and spontaneous abortion, although the prescribing information states that it is uncertain whether those cases were caused by the drugs. Developmental toxicity has also been observed in animal studies at clinically relevant exposures.

Bottom Line

Modafinil has a recognised safety profile that includes common adverse effects, uncommon serious reactions and risks that become more relevant in people with particular medical histories, interacting medications or prolonged sleep loss.

References

Apotex Corp. (2025). PROVIGIL (modafinil) tablets, for oral use: Prescribing information.

Kim, D. (2012). Practical use and risk of modafinil, a novel waking drug. Environmental Health and Toxicology, 27, e2012007. https://doi.org/10.5620/eht.2012.27.e2012007